Research Projects

Currently, Nanomedicine COE-TCR has six (6) focus/primary multidisciplinary research areas (shared amongst respective investigators) :

Targeted mitochondrial nanomedicines for control of cancer bioenergetics and induction of apoptosis

(Lead PIs: Weissig, Joshi and Elbayoumi)

Active research projects in this area:

  • Intracellular delivery of bortezomib using mitochondria targeted ceramide liposomes (Joshi's lab)
  • Neutralization of adriamycin-induced cadiotoxicity via mitochondria-targeted modulator-loaded nanocarriers (Elbayoumi's Lab)
  • Mitochondriotropic anticancer nanomedicines: drug/carrier design optimization and enhancement of in vitro / in vivo efficacy of mitochondria-specific flavonoid-loaded lipidic as adjuvants for anticancer chemotherapy (Elbayoumi's Lab)
  • Efficient liposomal delivery of synthetic phosphagen substrates to impair cancer cell bioenegrgetics and triggering apoptosis (Elbayoumi's Lab)

Nanoscale carriers of combination chemotherapy for treatment of multi-drug resistant tumors

(Lead PIs: Elbayoumi, and Vinay Janthakahalli)

Active research projects in this area:

  • Novel pro-apoptotic genistein-loaded lipidic nano-vesicles for anti-cancer chemotherapy, for resistant solid tumors over-expressing Pgp-efflux pump (Elbayoumis & Vinay Janthakahalli's labs)

Nano-biomaterials for chemotherapy of periodontal and oro-pharyngeal lesions

(Lead PIs: Mitchell, Wang and Elbayoumi)

Active research projects in this area:

  • Prototype lipo-polymeric muco-adhesive oral gel/buccal solid tablet and fast dissolving film delivery platforms for controlled localized delivery of gensitein against tongue and pharyngeal carcinoma lesions s (Elbayoumi's lab)
  • Multi-layered mucoadhesive tocotrienol-based nanoemulsion combination platform for clotrimazole against oro-pharryngeal cancers (Elbayoumi's & Mitchell's labs)

Targeted anti-angiogenic/vascular nano-therapy of cancer

(Lead PIs: Yao, Elbayoumi, and Hull)

Active research projects in this area:

  • Novel CD47-modified genistein liposomes as pro-apototic and antiangiogenic startegy against metastatic estrogen-dependednt tumors (Elbayoumi's lab)
  • Targeting TSP-1 for inhibition of solid cancer angiogenesis using CAM. (Yao's & Elbayoumi's labs)

Translational skin cancer chemo-protection and chemo-sensitization via cutaneous nano-composites

Lead PIs: Elbayoumi, Hull, and Averitte)

Active research projects in this area:

  • Development and in vitro/in vivo efficacy assessment of trans-dermal lipidic nanocarriers with vitamin E-matrix for combination chemotherapy for malignant skin melanomas (Elbayoumi's and Hull's labs, in collaboration with Avirette's ALBR)
  • Anti-oxidant-based nanoformulations for augmented chemo-prevention of photo-carcinogensis (Elbayoumi's labs)
  • Cationic niosomal platforms for active delivery of chemotherapeutic and chemopreventive agents against basal skin carcinomas (Elbayoumi's and Mitchell's labs)
  • Exosomes in Squamous Cell Carcinoma (SCC) and roles in metastasis and diagnosis (Hull's lab in collaboration with Avirette's ALBR)

Furthermore, each Nanomedicine-COE investigator's laboratory is also pursuing other independed nanoscale research projects/areas, as follows:

Dr. V. Weissig's Laboratory:

  1. Nanoliposome-based treatment of amyloid protein toxicity (Collaboration with Dr. Raymond Migrino, VA Hospital Phoenix, AZ)
  2. Bolaamphiphile-based nanocomplex delivery of antisense oligonucleotides to Clostridium difficile (Collaboration with Dr. David Stewart, Pennsylvania State University, College of Medicine, Hershey, PA)

Dr. M. Joshi's Laboratory:

  1. Design and development of a clinically acceptable, long circulating liposomal delivery system for IRL-1620 and its evaluation in cerebral ischemia rat models.

Dr. M. Yao's Laboratory:

  1. Mechanistic in vitro and ex-vivo evaluation of a novel pharmaceutical stargety for selective abrogation of TSP1-induced vascular dysfunction via decoy recombinant CD47 protein.

Dr. V. Wong's Laboratory:

  1. Differential Protein expression in primary and metastatic hemangiosarcoma tumors in dogs.

Dr. T. Elbayoumi's Laboratory:

  1. Engineering of block-polymerized liposomal nano-vehicles (Polysomes) for efficnet encapsulation of macromolecules (Si/micro RNA & peptides).
  2. Desing and in vitro assessment of hybrid nano-electrospun-3D printed scaffolds as alternative cancer models.

Dr. N. Janthakahalli's Laboratory:

  1. Sensors for cellular-imaging and biomolecule identification.
  2. Identifying glycans as cancer biomarkers and targets for therapy.

Dr. J. Gasiorowski's Laboratory:

  1. Studying cellular responses to nano and micro scale extracellular matrix geometries.
  2. Developing biomaterials to induce and direct nerve regeneration after traumatic injury.


Apply Now

Visit our

Take Tour

Support the

Donate to our future